文献速递神经肿瘤

GammaTile永久性脑植入物的剂量学评估与治疗计划考量——一项试点性机构经验

Dosimetric evaluation and treatment planning considerations for GammaTile permanent brain implants - a pilot, institutional experience.
PubMed 文献 · J Neurooncol · 2024-06-20

该研究回顾性分析了20例复发胶质母细胞瘤患者(21个病灶)接受切除术中GammaTile植入的机构经验,评估剂量学参数与临床结局。高危临床靶区D90中位值为56.0 Gy,6个月局部复发与D90相关(p=0.026),D90≥56 Gy组局部无复发生存有改善趋势(p=0.048)。

要点

  • 高危临床靶区D90中位值为56.0 Gy(范围31.7-98.7 Gy)。
  • 6个月局部复发与D90相关,提示剂量反应关系(p=0.026)。
  • D90≥56 Gy组局部无复发生存有改善趋势(p=0.048)。

核心结论

  • 本试点性机构经验提供了GammaTile近距离放疗的临床结局、剂量学考量及技术指导。

研究设计与样本

  • 回顾性分析2019年1月至2020年12月连续20例复发胶质母细胞瘤患者(21个病灶)接受切除术中GammaTile植入的机构经验。
  • 收集大体肿瘤体积、植入GammaTile单元数、高危临床靶区D90、危及器官剂量及6个月局部控制数据。

主要发现

  • 高危临床靶区D90中位值为56.0 Gy(范围31.7-98.7 Gy)。
  • 脑干、视交叉、同侧视神经、同侧海马中位Dmax分别为11.2、5.4、6.4、10.0 Gy。
  • 本队列无患者发生放射性坏死或归因于GammaTile的不良事件。
  • 术前大体肿瘤体积、切除腔体积与植入GammaTile单元数之间存在相关性。
  • 术后3个月MRI显示,7/21(33%)切除腔缩小,3/21(14%)稳定,11/21(52%)扩大。

关键数值与推荐

  • 高危临床靶区D90与GammaTile植入后6个月局部复发相关,提示剂量反应关系(p=0.026)。
  • 中位局部无复发生存期为366.5天(范围64-1098天)。
  • 高危临床靶区D90≥56 Gy组局部无复发生存有改善趋势(p=0.048)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: GammaTile® (GT) is a brachytherapy platform that received Federal Drug Administration (FDA) approval as brain tumor therapy in late 2018. Here, we reviewed our institutional experience with GT as treatment for recurrent glioblastomas and characterized dosimetric parameter and associated clinical outcome. METHODS AND MATERIALS: A total of 20 consecutive patients with 21 (n = 21) diagnosis of recurrent glioblastoma underwent resection followed by intraoperative GT implant between 01/2019 and 12/2020. Data on gross tumor volume (GTV), number of GT units implanted, dose coverage for the high-risk clinical target volume (HR-CTV), measured by D90 or dose received by 90% of the HR-CTV, dose to organs at risk, and six months local control were collected. RESULTS: The median D90 to HR-CTV was 56.0 Gy (31.7-98.7 Gy). The brainstem, optic chiasm, ipsilateral optic nerve, and ipsilateral hippocampus median Dmax were 11.2, 5.4, 6.4, and 10.0 Gy, respectively. None of the patients in this study cohort suffered from radiation necrosis or adverse events attributable to the GT. Correlation was found between pre-op GTV, the volume of the resection cavity, and the number of GT units implanted. Of the resection cavities, 7/21 (33%) of the cavity experienced shrinkage, 3/21 (14%) remained stable, and 11/21 (52%) of the cavities expanded on the 3-months post-resection/GT implant MRIs. D90 to HR-CTV was found to be associated with local recurrence at 6-month post GT implant, suggesting a dose response relationship (p = 0.026). The median local recurrence-free survival was 366.5 days (64-1,098 days), and a trend towards improved local recurrence-free survival was seen in patients with D90 to HR-CTV ≥ 56 Gy (p = 0.048). CONCLUSIONS: Our pilot, institutional experience provides clinical outcome, dosimetric considerations, and offer technical guidance in the clinical implementation of GT brachytherapy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Zhang S, Patel K, Dusenbery K, et al. Dosimetric evaluation and treatment planning considerations for GammaTile permanent brain implants - a pilot, institutional experience. J Neurooncol. 2024. PMID: 38902561. doi:10.1007/s11060-024-04631-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。